18.3 Cytokine Release Syndrome

CPHON TCO V.C.4 is cytokine release syndrome (CRS) as an emergency, not as a manufacturing lecture. The full chimeric antigen receptor T-cell (CAR-T) sequence—leukapheresis, lymphodepleting fludarabine plus cyclophosphamide, infusion, expansion, and B-cell aplasia with intravenous immunoglobulin—lives in the cellular-therapy chapter. This section is what you do when fever, leak, hypoxia, and hypotension start hours to days after the cells or the bispecific antibody are in the child.

Who gets CRS and when

CRS follows immune-effector cell therapy: CD19 CAR-T for relapsed or refractory B-ALL (and some lymphomas) and bispecific T-cell engagers such as blinatumomab (a continuous CD19/CD3 infusion). Other T-cell–engaging antibodies can do the same. It is interleukin-6 (IL-6)–driven macrophage and T-cell activation, not a simple drug fever and not graft-versus-host disease from a transplant graft. CAR-T is not hematopoietic stem cell transplantation.

Timing is hours to days after infusion, product-dependent. Blinatumomab CRS often declares on the first cycle, sometimes within hours of the bag starting or the rate stepping up. CAR-T CRS commonly appears during in vivo expansion in the first many days after infusion, not during the manufacturing week when the child is still waiting for the bag. A 9-year-old who looks well the evening of CAR-T infusion and spikes 39.2°C on day 4 is in the CRS window until proven otherwise. A 7-year-old whose parent disconnected a blinatumomab pump and who then becomes febrile and hypotensive after restart is also in the CRS window—and the line interruption is a separate medication-safety event.

Do not teach that CRS “only happens in the ICU after transplant.” Do not teach that isolated fever two days after cells “cannot be CRS because it is too late” or “too early.” Hours to days is the exam range.

Fever first, then leak

Fever is the first and grade-defining clinical move in commonly used systems. Then comes capillary leak: third-spacing, edema, weight gain, pulmonary edema, hypoxia, and hypotension. Coagulopathy, transaminitis, and tachycardia travel with higher-grade disease. A child can climb from “just febrile” to vasopressor shock in hours. That is why cellular-therapy fever is a stay-and-notify finding, not a playroom suggestion.

American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading is the language most pediatric cellular-therapy programs use. Teach the concept, not a claim that ONCC printed the table:

• Grade opens with fever.
• The grade rises when hypotension needs more than fluids (vasopressors) or when hypoxia needs increasing oxygen support.
• Higher grades are ICU physiology: pressors, high-flow oxygen, positive-pressure ventilation.

You will not be scored on reciting every oxygen-device cutoff as if it were an ONCC fact. You will be scored on recognizing that fever plus leak is CRS, that oxygen and blood pressure define severity, and that the floor is not the place to “watch” refractory shock.

A 9-year-old on nasal cannula with a falling blood pressure is already a different grade from the same child who was only febrile an hour ago. Call early. Serial vital signs, work of breathing, and weights catch leak before the chest radiograph does.

Tocilizumab, steroids, fluids, ICU

Tocilizumab, an IL-6 receptor antagonist, is the targeted drug for CRS that meets protocol treatment criteria (typically hypotension, hypoxia, or a rapid grade rise—not every isolated low-grade fever). Give it as ordered. Do not wait for a code. Repeat doses follow the product protocol.

Corticosteroids (often dexamethasone) treat refractory CRS and are first-line for significant immune effector cell–associated neurotoxicity syndrome (ICANS) overlap: aphasia, seizure, ICE-style encephalopathy, cerebral edema. For many CRS protocols, steroids come after tocilizumab because they can dampen CAR-T activity. Isolated ICANS without CRS is a steroid-and-neuro problem; tocilizumab is not the automatic first drug for a child who is only aphasic and not leaking. ICE-style checks still run on a clock during the CRS window. A 12-year-old who cannot write her name the morning after fever is ICANS until proven otherwise, even if blood pressure has recovered.

Fluids are given carefully. Capillary leak means the bolus you would give a septic toddler can flood the lungs. Use protocol-sized boluses, reassess, and move to vasopressors and ICU rather than stacking milliliters. Weigh every shift. Crackles plus a 1-kg gain in a 20-kg child is leak.

Rule out sepsis and treat both until proven. Febrile neutropenia plus CRS is not a multiple-choice fork where you pick only one. Culture, give broad-spectrum antibiotics per fever-and-neutropenia protocol, and treat CRS. Withholding antibiotics “to protect the cells” is how children die of bacterial sepsis that looked like grade 1 CRS. Conversely, antibiotics alone without notifying the cellular-therapy team miss the IL-6 emergency.

Stop or hold blinatumomab per protocol for CRS; never bolus a continuous bag to “catch up” after a pause. CAR-T cells are already in; you cannot take them back, so management is tocilizumab, support, steroids as indicated, and organ support. Premedication and line-security rules for blinatumomab belong with immunotherapy administration; the emergency product here is fever-then-leak after the bag is already running.

A pediatric picture that holds

A 9-year-old day-4 post CD19 CAR-T: fever 39.4°C, then nasal-cannula oxygen, then a falling blood pressure with puffy eyelids. Culture and antibiotics. Notify. Tocilizumab as ordered. Careful fluids. Telemetry and ICE-style neuro checks because ICANS may follow. ICU when oxygen or blood pressure is no longer a floor problem. A 7-year-old on blinatumomab with the same physiology: hold the infusion, same dual infection-plus-CRS path, same tocilizumab conversation, same leak-aware fluids. A toddler too young for a classic ICE score still gets a neurologic check: tracking, speech, seizure watch, and a low threshold to call.

That is the emergency chapter: fever first, dual-treat infection, grade by oxygen and blood pressure, tocilizumab for CRS, steroids for refractory disease and ICANS, fluids with leak in mind, hours-to-days timing, and no CAR-T factory lecture on this page.